Bristol/Teva “Authorized” Generic Agreement Approved By FTC
Executive Summary
The Federal Trade Commission is giving its formal blessing to an "authorized" generic agreement between Bristol-Myers Squibb and Teva involving the first generic version of Paraplatin (carboplatin)